Histone demethylase LSD1 plays key roles during carcinogenesis, targeting LSD1 is
becoming an emerging option for the treatment of cancers. Numerous LSD1 inhibitors have …

Histone lysine-specific demethylase 1 (LSD1/KDM1A) was first identified in 2004 as an
epigenetic enzyme able to demethylate specific lysine residues of histone H3, namely …

Natural products generally fall into the biologically relevant chemical space and always
possess novel biological activities, thus making them a rich source of lead compounds for …

Histone lysine-specific demethylase 1 (LSD1/KDM1A) has become an important and
promising anticancer target since it was first identified in 2004 and specially demethylates …

Gene mutations are strongly associated with tumor progression and are well known in
cancer development. However, recently discovered epigenetic alterations have shown the …

As a flavin adenine dinucleotide (FAD)-dependent monoamine oxidase, lysine specific
demethylase 1 (LSD1/KDM1A) functions as a transcription coactivator or corepressor to …

Recently, despite the great success achieved by the so‐called “magic bullets” in the
treatment of different diseases through a marked and specific interaction with the target of …

LSD1 has become an important biologically validated epigenetic target for cancer therapy
since its identification in 2004. LSD1 mediates many cellular signaling pathways and is …

The orexin system, which consists of the two G protein-coupled receptors OX1 and OX2,
activated by the neuropeptides OX-A and OX-B, is firmly established as a key regulator of …

Breast cancer (BC) is a kind of malignant cancer in women, and it has become the most
diagnosed cancer worldwide since 2020. Histone methylation is a common biological …